Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

b. braun medical limited - leucine isoleucine lysine hydrochloride dl-methionine phenylalanine threonine tryptophan, l- valine arginine histidine aminoacetic acid alanine proline aspartic acid aspargine monohydrate acetylcysteine glutamic acid ornithine hydrochloride serine tyrosine sodium acetate trihydrate potassium acetate magnesium acetate tetrahydrate sodium phosphate monobasic malic acid n-acetyltyrosine ph. eur. - solution for infusion - 10 %w/v

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

b. braun medical limited - leucine isoleucine lysine hydrochloride dl-methionine phenylalanine threonine tryptophan, l- valine arginine histidine aminoacetic acid alanine proline aspartic acid aspargine monohydrate acetylcysteine glutamic acid ornithine hydrochloride serine tyrosine sodium acetate trihydrate potassium acetate magnesium acetate tetrahydrate sodium phosphate monobasic malic acid n-acetyltyrosine ph. eur. - solution for infusion - 10 %w/v

Austraalia - inglise - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - isoleucine - l - unknown - isoleucine - l amino acid-isoleucine-l active 0.0 - active constituent

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

hospira, inc. - isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77) - isoleucine 990 mg in 100 ml

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

b. braun medical inc. - isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77), leucine (unii: gmw67qnf9c) (leucine - unii:gmw67qnf9c), lysine acetate (unii: ttl6g7liwz) (lysine - unii:k3z4f929h6), methionine (unii: ae28f7pnpl) (methionine - unii:ae28f7pnpl), phenylalanine (unii: 47e5o17y3r) (phenylalanine - unii:47e5o17y3r), threonine (unii: 2zd004190s) (threonine - unii:2zd004190s), tryptophan (unii: 8duh1n11bx) (tryptophan - unii:8duh1n11bx), valine (unii: hg18b9yrs7) (valine - unii:hg18b9yrs7), cysteine hydrochlo - isoleucine 0.49 g in 100 ml - trophamine® is indicated for the nutritional support of infants (including those of low birth weight) and young pediatric patients requiring tpn via either central or peripheral infusion routes. parenteral nutrition with trophamine® is indicated to prevent nitrogen and weight loss or treat negative nitrogen balance in infants and young pediatric patients where (1) the alimentary tract, by the oral, gastrostomy, or jejunostomy route, cannot or should not be used, or adequate protein intake is not feasible by these routes; (2) gastrointestinal absorption of protein is impaired; or (3) protein requirements are substantially increased as with extensive burns. dosage, route of administration, and concomitant infusion of non-protein calories are dependent on various factors, such as nutritional and metabolic status of the patient, anticipated duration of parenteral nutritional support, and vein tolerance. see warnings , precautions, pediatric use , and dosage and administration . central venous infusion should b

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

baxter healthcare corporation - leucine (unii: gmw67qnf9c) (leucine - unii:gmw67qnf9c), phenylalanine (unii: 47e5o17y3r) (phenylalanine - unii:47e5o17y3r), lysine (unii: k3z4f929h6) (lysine - unii:k3z4f929h6), methionine (unii: ae28f7pnpl) (methionine - unii:ae28f7pnpl), isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77), valine (unii: hg18b9yrs7) (valine - unii:hg18b9yrs7), histidine (unii: 4qd397987e) (histidine - unii:4qd397987e), threonine (unii: 2zd004190s) (threonine - unii:2zd004190s), tryptophan (unii: 8duh1n11bx - leucine 201 mg in 100 ml - clinimix e is indicated as a source of calories, protein, and electrolytes for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. clinimix e may be used to treat negative nitrogen balance in patients. there are no adequate or well-controlled studies in pregnant women with clinimix e. additionally, animal reproduction studies have not been conducted with amino acids and electrolytes and dextrose. it is not known whether clinimix e can cause fetal harm when administered to a pregnant woman. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. however, the estimated background risk in the u.s. general population of major birth defects is 2 to 4% and of miscarriage is 15 to 20% of clinically recognized pregnancies. disease-associated maternal and/or embryo-fetal risk based on clinical practice guidelines, parenteral nutrition should be considered in cases of severe maternal malnutriti

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

baxter healthcare corporation - leucine (unii: gmw67qnf9c) (leucine - unii:gmw67qnf9c), phenylalanine (unii: 47e5o17y3r) (phenylalanine - unii:47e5o17y3r), lysine (unii: k3z4f929h6) (lysine - unii:k3z4f929h6), methionine (unii: ae28f7pnpl) (methionine - unii:ae28f7pnpl), isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77), valine (unii: hg18b9yrs7) (valine - unii:hg18b9yrs7), histidine (unii: 4qd397987e) (histidine - unii:4qd397987e), threonine (unii: 2zd004190s) (threonine - unii:2zd004190s), tryptophan (unii: 8duh1n11bx - leucine 201 mg in 100 ml - clinimix is indicated as a source of calories and protein for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. clinimix may be used to treat negative nitrogen balance in patients. the use of clinimix is contraindicated in: risk summary there are no adequate or well-controlled studies in pregnant women with clinimix. additionally, animal reproduction studies have not been conducted with amino acids and electrolytes and dextrose. it is not known whether clinimix can cause fetal harm when administered to a pregnant woman. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. however, the estimated background risk in the u.s. general population of major birth defects is 2 to 4% and of miscarriage is 15 to 20% of clinically recognized pregnancies. clinical considerations disease-associated maternal and/or embryo-fetal risk based on clinical practice guidelines, parenteral nutrition sh

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

hospira, inc. - isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77) - isoleucine 620 mg in 100 ml

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

hospira, inc. - isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77) - isoleucine 462 mg in 100 ml

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

hospira, inc. - isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77) - isoleucine 252 mg in 100 ml